[go: up one dir, main page]

AR045738A1 - Derivados de bencimidazol n3 alquilados como inhibidores de mek - Google Patents

Derivados de bencimidazol n3 alquilados como inhibidores de mek

Info

Publication number
AR045738A1
AR045738A1 ARP040103103A ARP040103103A AR045738A1 AR 045738 A1 AR045738 A1 AR 045738A1 AR P040103103 A ARP040103103 A AR P040103103A AR P040103103 A ARP040103103 A AR P040103103A AR 045738 A1 AR045738 A1 AR 045738A1
Authority
AR
Argentina
Prior art keywords
aryl
heteroaryl
heterocyclyl
nr3r4
alkyl
Prior art date
Application number
ARP040103103A
Other languages
English (en)
Inventor
Eli M Wallace
Joseph Lyssikatos
Allison L Marlow
T Brian Hurley
Kevin Koch
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR045738A1 publication Critical patent/AR045738A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una prodroga de fosfato o aminoácido de un compuesto (1H-benzoimidazol-5-il) (fenil 4-sustituido)-amina alquilada que tiene la fórmula (1) y sales farmacéuticamente aceptables, prodrogas y solvatos de ellos, en donde: ------- es un enlace opcional, siempre que uno y sólo un N del anillo tenga enlace doble; R1, R9 y R10 ase seleccionan independientemente de H, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, - NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, -S(O)j(alquilo C1-6), -S(O)j(CR4R5)m-arilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -O(CR4R5)m-arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, -NR4(CR4R5)m-heteroarilo, -O(CR4R5)m-heterociclilo o -NR4(CR4R5)m-heterociclilo, donde cada porción de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a cinco grupos que se seleccionan independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, - NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R3 se selecciona de H, trifluorometilo, alquilo C1-10, alquenilo, C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a cinco grupos que se seleccionan independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, fosfato, residuo de aminoácido, polipéptido, hemisuccinato, ésteres de fosfato, dimetilaminoacetato, fosforilmetiloxicarbonilo, fosfonamida, -NR´SO2R""´, -SO2NR´R", -C(O)R´, -C(O)OR´, -OC(O)R´, -NR´C(O)OR"", -NR´C(O)R", -C(O)NR´R", -SR´, -S(O)R"", -SO2R"", - NR´R", -NR´C(O)NR"R"´, -NR¨C(NCN)NR"R"¨, -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo, o R3 y R4 junto con el átomo al cual están unidos forman un anillo carbocíclico, de heteroarilo o heterociclilo de 4 a 10 miembros, cada uno de los cuales se sustituye optativamente con uno a tres grupos que se seleccionan independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR´SO2R"", -SO2NR´R", -C(O)R´, - C(O)OR´, -OC(O)R´, -NR´C(O)OR"", -NR´C(O)R", -C(O)NR´R", - SO2R"", -NR´R", -NR´C(O)NR"R"´, -NR´C(NCN)NR"R"´, -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R´, R" y R"´se seleccionan independientemente de H, alquilo inferior, alquenilo inferior, arilo y arilalquilo; R"" se selecciona de alquilo inferior, alquenilo inferior, arilo y arilalquilo; o dos cualquiera de R´, R", R"´o R"" junto con el átomo al cual están unidos, forman un anillo carbocíclico, de heteroarilo o heterocíclico de 4 a 10 miembros, cada uno de los cuales se sustituye optativamente con uno a tres grupos que se seleccionan independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R4 y R5 representan independientemente H o alquilo C1-6, o R4 y R5 junto con el átomo al cual están unidos forman un anillo carbocíclico de heteroarilo o heterocíclico de 4 a 10 miembros, cada uno de los cuales se sustituye optativamente con uno a tres grupos que se seleccionan independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR´SO2R"", -SO2NR´R", -C(O)R´, -C(O)OR´, -OC(O)R´, -NR´C(O)OR"", -NR´C(O)R", -C(O)NR´R", - SO2R"", -NR´R", -NR´C(O)NR"R"´, -NR´C(NCN)NR"R"´, -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R6 se selecciona de trifluorometilo, alquilo C1-10, cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, en donde cada porción de alquilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a tres grupos oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR´SO2R"", -SO2NR´R", -C(O)R´, -C(O)OR´, -OC(O)R´, -NR´C(O)OR"", -NR´C(O)R", -C(O)NR´R", - SO2R"", - NR´R", -NR´C(O)NR"R"´, -NR´C(NCN)NR"R"´, -OR´, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; R7 se selecciona, de alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3- 10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a cinco grupos que se seleccionan independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -SO2R6, -NR3R4, -NR5C(O)NR3R4, - NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; W se selecciona de heteroarilo, heterociclilo, -C(O)R3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)R4OR3, -C(O)(cicloalquilo C3-10), -C(O)(alquilo C1- 10), -C(O)(arilo), -C(O)(heteroarilo) y -C(O)(heterociclilo), cada uno de los cuales se sustituye optativamente con 1-5 grupos que se seleccionan de: -NR3R4, -OR3, -R2, alquilo C1-10, alquenilo C2-10, y alquinilo C2-10, cada uno de los cuales se sustituye optativamente con 1 o 2 grupos que se seleccionan independientemente de --NR3R4 y -OR3; R8 se selecciona de H, -SCF3, -Cl. -Br, -F, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -OR3, -C(O)R3, -C(O)OR3, - NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR3R4, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, S(O)j(alquilo C1-6), -S(O)j(CR4R5)m-arilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -O(CR4R5)m-arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, -NR4(CR4R5)m-heteroarilo, -O(CR4R5)m-heterociclilo o -NR4(CR4R5)m-heterociclilo, donde cada porción de alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo y heterociclilo se sustituye optativamente con uno a cinco grupos que se seleccionan independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, - NR4SO2R6, SO2NE3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, y heterociclilalquilo; m es 0, 1, 2, 3, 4º 5; y j es 1 o 2. Composición que comprende dicho compuesto y un portador farmacéuticamente aceptable. Uso de dicho compuesto para fabricar la composición farmacéutica útil para inhibir la actividad de MEK es un mamífero que lo necesita. Uso de dicho compuesto para fabricar una composición farmacéutica para el tratamiento de un trastorno hiperproliferativo en un mamífero que lo necesita mediante la administración de una cantidad eficaz para tratar ese trastorno.
ARP040103103A 2003-08-29 2004-08-27 Derivados de bencimidazol n3 alquilados como inhibidores de mek AR045738A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/652,733 US7235537B2 (en) 2002-03-13 2003-08-29 N3 alkylated benzimidazole derivatives as MEK inhibitors

Publications (1)

Publication Number Publication Date
AR045738A1 true AR045738A1 (es) 2005-11-09

Family

ID=34273411

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103103A AR045738A1 (es) 2003-08-29 2004-08-27 Derivados de bencimidazol n3 alquilados como inhibidores de mek

Country Status (18)

Country Link
US (2) US7235537B2 (es)
EP (1) EP1663210B1 (es)
JP (1) JP5026076B2 (es)
KR (1) KR20060121853A (es)
CN (1) CN1874768A (es)
AR (1) AR045738A1 (es)
AU (1) AU2004270166A1 (es)
BR (1) BRPI0413152A (es)
CA (1) CA2537098A1 (es)
ES (1) ES2628959T3 (es)
IL (1) IL173935A (es)
IS (1) IS8384A (es)
MX (1) MXPA06002268A (es)
NO (1) NO20061432L (es)
RU (1) RU2006109600A (es)
TW (1) TW200524879A (es)
WO (1) WO2005023251A1 (es)
ZA (1) ZA200602588B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101486682B (zh) * 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
CA2532067C (en) * 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
CN102786482A (zh) * 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
TW201238952A (en) 2005-05-18 2012-10-01 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof
PT1934174E (pt) 2005-10-07 2011-07-14 Exelixis Inc Azetidinas como inibidores de mek para o tratamento de doenças proliferativas
ATE507224T1 (de) 2005-11-15 2011-05-15 Array Biopharma Inc Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US20090030058A1 (en) * 2005-12-21 2009-01-29 Mohammed Pervez Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
ATE493418T1 (de) 2006-07-06 2011-01-15 Array Biopharma Inc Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
RS52210B (en) * 2006-07-06 2012-10-31 Array Biopharma, Inc. CYCLOPENT [D] PYRIMIDINS AS PROTEIN KINASE ACTION INHIBITORS
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US7855216B2 (en) 2006-11-30 2010-12-21 Genentech, Inc. Aza-indolyl compounds and methods of use
JP5311673B2 (ja) * 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
KR101650956B1 (ko) 2007-07-05 2016-08-24 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
ES2533557T3 (es) * 2007-07-05 2015-04-13 Array Biopharma, Inc. Pirimidil ciclopentanos como inhibidores de proteína cinasa AKT
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CN101778839A (zh) 2007-08-16 2010-07-14 霍夫曼-拉罗奇有限公司 取代的乙内酰脲
ES2456966T3 (es) 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
JP2011506420A (ja) * 2007-12-12 2011-03-03 アストラゼネカ アクチボラグ Ｍｅｋ阻害剤及びオーロラキナーゼ阻害剤１８８を含んでなる組合せ
MX2010006331A (es) 2007-12-20 2010-07-05 Hoffmann La Roche Hidantoinas sustituidas como inhibidores de cinasa mek.
AU2009204019B2 (en) * 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
JP5346345B2 (ja) * 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP2011527703A (ja) 2008-07-11 2011-11-04 ノバルティス アーゲー （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
ES2399384T3 (es) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido fenoxibenzamidas sustituidas
MA33974B1 (fr) * 2009-10-12 2013-02-01 Hoffmann La Roche Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek
CA2777071A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
KR20130113430A (ko) 2010-08-05 2013-10-15 케이스 웨스턴 리저브 유니버시티 신경 연결의 발달 장애에 대한 ｅｒｋ 억제제
DK2624696T3 (en) 2010-10-06 2017-03-13 Glaxosmithkline Llc Corp Service Company BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS
EP2632899A1 (en) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Substituted phenoxypyridines
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
EP2655375B1 (fr) 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
KR20140025434A (ko) 2011-04-01 2014-03-04 제넨테크, 인크. Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법
CA2836364C (en) 2011-05-25 2021-01-26 Universite Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
MA37405A1 (fr) 2012-03-14 2016-03-31 Lupin Ltd Composés hétérocyclyle
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
PT3702351T (pt) 2012-10-19 2024-01-17 Array Biopharma Inc Formulação contendo um inibidor de mek
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
MX2015013466A (es) 2013-03-21 2016-06-21 Novartis Ag Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor.
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
WO2016009306A1 (en) 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
WO2016035008A1 (en) 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
KR102439911B1 (ko) * 2016-06-03 2022-09-05 어레이 바이오파마 인크. 제약학적 복합제제
WO2019096112A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
US11078194B2 (en) * 2017-12-07 2021-08-03 Harbin Zhenbao Pharmaceutical Co., Ltd. Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor
FI3853220T3 (fi) 2018-09-18 2024-02-22 Hoffmann La Roche Kinatsoliinijohdannaisia antitumoraalisina aineina
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
US11447482B1 (en) 2019-02-14 2022-09-20 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法
CN115490640B (zh) * 2021-06-17 2024-11-26 深圳市塔吉瑞生物医药有限公司 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
EP4367112A1 (en) 2021-07-09 2024-05-15 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
CN116135839A (zh) * 2021-11-18 2023-05-19 江苏润安制药有限公司 一种阿齐沙坦关键中间体的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750545A (en) * 1993-07-23 1998-05-12 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
KR20010014362A (ko) 1997-07-01 2001-02-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 4-브로모 또는 4-요오도 페닐아미노 벤즈히드록삼산유도체 및 ｍｅｋ 억제제로서의 그의 용도
BR9810385A (pt) 1997-07-01 2000-09-05 Warner Lambert Co Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
WO2000040235A2 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Treatment of asthma with mek inhibitors
JP2002534446A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー ４′ヘテロアリールジアリールアミン
HUP0105092A3 (en) * 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
BR9916894A (pt) 1999-01-13 2001-11-20 Warner Lambert Co ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
EP1144371B1 (en) 1999-01-13 2005-11-09 Warner-Lambert Company Llc Benzenesulphonamide derivatives and their use as mek inhibitors
BR9916904A (pt) * 1999-01-13 2001-10-30 Warner Lambert Co Benzo heterociclos e seu uso como inibidores demek
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
AU5786000A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
US7030119B1 (en) * 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
KR20020015376A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법
HUP0202180A3 (en) 1999-07-16 2004-10-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
CA2377100A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
WO2001068619A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
US7001905B2 (en) * 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
EE05450B1 (et) * 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
BR0113520A (pt) 2000-08-25 2003-06-24 Warner Lambert Co Processo de preparação de ácidos n-aril-antranìlicos e seus derivados
JP2004514718A (ja) * 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ 抗癌剤としての置換キノリン類
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
CN101486682B (zh) * 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
DOP2003000614A (es) * 2002-03-13 2009-09-30 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole
CA2532067C (en) * 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles

Also Published As

Publication number Publication date
ES2628959T3 (es) 2017-08-04
JP2007504139A (ja) 2007-03-01
NO20061432L (no) 2006-08-25
US7235537B2 (en) 2007-06-26
AU2004270166A1 (en) 2005-03-17
RU2006109600A (ru) 2007-10-10
ZA200602588B (en) 2008-07-30
US7842816B2 (en) 2010-11-30
IS8384A (is) 2006-03-29
EP1663210A1 (en) 2006-06-07
JP5026076B2 (ja) 2012-09-12
CA2537098A1 (en) 2005-03-17
EP1663210A4 (en) 2009-04-22
IL173935A0 (en) 2006-07-05
EP1663210B1 (en) 2017-04-19
BRPI0413152A (pt) 2006-10-03
WO2005023251A1 (en) 2005-03-17
TW200524879A (en) 2005-08-01
MXPA06002268A (es) 2006-05-31
KR20060121853A (ko) 2006-11-29
IL173935A (en) 2015-08-31
US20040116710A1 (en) 2004-06-17
CN1874768A (zh) 2006-12-06
US20070299063A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
AR045738A1 (es) Derivados de bencimidazol n3 alquilados como inhibidores de mek
AR038971A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR038881A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos
AR051403A1 (es) Derivados de purina, purinona y deazapurina como inhibidores de la actividad de la protein quinasa; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la protein quinasa a y b.
AR038972A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR076460A1 (es) Antagonistas del receptor cxcr3
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR039673A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion
AR038883A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos
AR044134A1 (es) Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
AR072227A1 (es) Derivados de triazinona sustituidos
BRPI0619823A8 (pt) compostos que são inibidores de erk
BR112015015812A2 (pt) derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor
AR046272A1 (es) Inhibidores de dipeptidil peptidasa iv
EA202090658A1 (ru) Ингибиторы кэп-зависимой эндонуклеазы
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
AR046081A1 (es) Inhibidores heterociclicos de mek y uso de los mismos
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
UY28144A1 (es) Agentes terapéuticos
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal
FB Suspension of granting procedure